157 related articles for article (PubMed ID: 34105465)
41. Prognostic value of whole-body dynamic
Yin J; Wang H; Zhu G; Chen N; Khan MI; Zhao Y
Heliyon; 2023 Sep; 9(9):e19749. PubMed ID: 37809527
[TBL] [Abstract][Full Text] [Related]
42. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
Cahu X; Bodet-Milin C; Brissot E; Maisonneuve H; Houot R; Morineau N; Solal-Celigny P; Godmer P; Gastinne T; Moreau P; Moreau A; Lamy T; Kraber-Bodere F; Le Gouill S
Ann Oncol; 2011 Mar; 22(3):705-711. PubMed ID: 20739714
[TBL] [Abstract][Full Text] [Related]
43. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
44. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.
Zhou Z; Chen C; Li X; Li Z; Zhang X; Chang Y; Lu L; Cui Y; Ma Y; Zhang M
Ann Hematol; 2015 Jun; 94(6):963-7. PubMed ID: 25547320
[TBL] [Abstract][Full Text] [Related]
46. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
47. Metabolic activity of extranodal NK/T cell lymphoma on
Lim CH; Yoon SE; Kim SJ; Cho J; Ko YH; Lee KH; Kim WS
Sci Rep; 2021 Mar; 11(1):5879. PubMed ID: 33723329
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
[TBL] [Abstract][Full Text] [Related]
49. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
50. Intratumoral Heterogeneity of Pretreatment 18F-FDG PET Images Predict Disease Progression in Patients With Nasal Type Extranodal Natural Killer/T-cell Lymphoma.
Ko KY; Liu CJ; Ko CL; Yen RF
Clin Nucl Med; 2016 Dec; 41(12):922-926. PubMed ID: 27749404
[TBL] [Abstract][Full Text] [Related]
51. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
52. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
[No Abstract] [Full Text] [Related]
53. [Value of PET/CT in the prognosis of extranodal NK/T cell lymphoma].
Dong GH; Li Y; Wan HF; He CY; Yang L; Wang JW; Gong LP; Zhao YH; Gao ZF; Liu HG
Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1256-1260. PubMed ID: 29747315
[No Abstract] [Full Text] [Related]
54. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
[TBL] [Abstract][Full Text] [Related]
55. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
56. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
[TBL] [Abstract][Full Text] [Related]
57. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
58. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
59. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]